India, Aug. 19 -- CARsgen Therapeutics Holdings Limited (2171.HK), a clinical-stage biopharmaceutical company, on Wednesday announced its 2026 interim half year results, and provided several clinical updates.
Company Profile
The company is based in China and the U.S. and is focused on developing innovative CAR T-cell therapies for hematologic malignancies and solid tumors.
CARsgen's pipeline includes:
Autologous CAR-T cell therapies- satri-cel (CT041), a Claudin18.2-targeted CAR T-cell therapy for solid tumors; and zevorcabtagene autoleucel (zevor-cel), a BCMA-targeted CAR T therapy for relapsed/refractory multiple myeloma (R/R MM).
Several allogenic and in vivo CAR-T candidates designed to target BCMA, CLL1, claudin 18.2 receptors, fo...